Filing search / Olema Pharmaceuticals, Inc. / "Reimbursement"

Search information

Olema Pharmaceuticals, Inc.

Companies

"Reimbursement"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

55 results

Newest first Best match first

10-Q

2024 Q2

OLMA Olema Pharmaceuticals, Inc.

Quarterly report

reimbursement amount. As of June 30, 2024, there was no outstanding balance from the receivable due from Novartis. Clinical Trial Agreement … to reimbursement of, clinical trial costs under collaboration agreements, if any; the costs of preparing, filing and prosecuting patent applications

6 Aug 24

4:15pm

10-Q

2024 Q1

OLMA Olema Pharmaceuticals, Inc.

Quarterly report

reflected as a reduction of such expenses. As of December 31, 2023, the Company had incurred the full agreed-upon reimbursement amount. As of March 31 … , or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any; the costs of preparing, filing and prosecuting patent

8 May 24

4:15pm

10-K

2023 FY

OLMA Olema Pharmaceuticals, Inc.

Annual report

of palazestrant, OP-3136 and any other product candidates we may develop, as well as the pricing and reimbursement of palazestrant, OP-3136 and any other product … of Contents Pharmaceutical coverage, pricing and reimbursement Significant uncertainty exists as to the coverage and reimbursement status of any

11 Mar 24

4:15pm

10-K

2023 FY

EX-97.1

OLMA Olema Pharmaceuticals, Inc.

Annual report

any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification

11 Mar 24

4:15pm

10-K

2023 FY

EX-1.1

OLMA Olema Pharmaceuticals, Inc.

Annual report

reimbursement not to exceed $25,000 and, (viii) the reasonable fees and disbursements of the Agent’s counsel in the amount of (a) $75,000 for the initial … , or otherwise, except with respect to reimbursement of expenses pursuant to Section 7(g). (f) Any termination of this Agreement shall be effective

11 Mar 24

4:15pm

424B3

uxcn1 dr5mvfv2iui

12 Feb 24

Prospectus supplement

31 Jan 24

4:21pm

424B5

qoktyeqgbxdv7r m7ss

5 Jan 24

Prospectus supplement for primary offering

7 Nov 23

4:12pm

Olema Oncology Announces Combined Financing for Up to $180 Million

8 Aug 23

4:12pm

9 May 23

4:08pm

9 May 23

4:08pm

9 May 23

4:08pm

10-Q

wmalb1jalkcf vj1ik

Quarterly report

9 May 23

4:08pm

Amendments to Articles of Incorporation or Bylaws

8 Nov 22

4:45pm

9 Aug 22

12:00am

10-Q

06dz3z2jf whsubc92v

Quarterly report

9 Aug 22

12:00am

10-Q

6s8fojlu056 it2

Quarterly report

9 May 22

4:44pm

Filing search / Olema Pharmaceuticals, Inc. / "Reimbursement"

55 results

Top filers

Top filing types

Recent filing years